Paediatric Onco Hematology Unit

Hôpital-Camfrout, France

Paediatric Onco Hematology Unit

Hôpital-Camfrout, France
SEARCH FILTERS
Time filter
Source Type

Jourdain A.,Paediatric Onco Hematology Unit | Auperin A.,Biostatistics and Epidemiology Unit | Minard-Colin V.,Gustave Roussy | Aladjidi N.,Bordeaux University Hospital Center | And 8 more authors.
Haematologica | Year: 2015

To describe relapsed B-cell lymphoma or leukemia in children/adolescents treated with a “Lymphomes Malins B” regimen and their outcome and to identify prognostic factors for survival, we studied relapses in the LMB89, 96 and 2001 studies of the Société Française d’Oncologie Pédiatrique (Société Française des Cancers de l’Enfant). Therapeutic guidelines at relapse were to obtain a second complete remission and to consolidate the remission with high-dose chemotherapy followed by autologous stem-cell transplantation. Between July 1989 and March 2007, 67 patients of 1322 (5%) relapsed: 57 had Burkitt lymphoma and 10 had large-cell histology. Three patients were initially treated in risk group A, 41 in group B and 23 in group C. Thirty-three patients had a relapse in one site (15 in the central nervous system) and 34 at multiple sites. Sixty-five patients received salvage chemotherapy and 33 achieved complete remission. Forty-one patients also received high-dose chemotherapy followed by autologous (n=33) or allogeneic (n=8) transplantation. With a median follow-up of 6.4 years, the 5-year survival rate was 29.9%. Nineteen patients were still alive, all but one (group A) received consolidation treatment. Multivariate analysis showed the following factors to be significantly associated with better survival: relapse at one site (P=0.0006), large-cell histology (P=0.012), initial prognostic group A or B with lactate dehydrogenase level below twice the normal value (P=0.005), and time to relapse more than 6 months (P=0.04). © 2015 Ferrata Storti Foundation.


PubMed | Emma Childrens Hospital Academic Medical Center, Aix - Marseille University, Biostatistics and Epidemiology Unit, Institute of Pediatric Hematology and Oncology and 5 more.
Type: Journal Article | Journal: Haematologica | Year: 2015

To describe relapsed B-cell lymphoma or leukemia in children/adolescents treated with a Lymphomes Malins B regimen and their outcome and to identify prognostic factors for survival, we studied relapses in the LMB89, 96 and 2001 studies of the Socit Franaise dOncologie Pdiatrique (Socit Franaise des Cancers de lEnfant). Therapeutic guidelines at relapse were to obtain a second complete remission and to consolidate the remission with high-dose chemotherapy followed by autologous stem-cell transplantation. Between July 1989 and March 2007, 67 patients of 1322 (5%) relapsed: 57 had Burkitt lymphoma and 10 had large-cell histology. Three patients were initially treated in risk group A, 41 in group B and 23 in group C. Thirty-three patients had a relapse in one site (15 in the central nervous system) and 34 at multiple sites. Sixty-five patients received salvage chemotherapy and 33 achieved complete remission. Forty-one patients also received high-dose chemotherapy followed by autologous (n=33) or allogeneic (n=8) transplantation. With a median follow-up of 6.4 years, the 5-year survival rate was 29.9%. Nineteen patients were still alive, all but one (group A) received consolidation treatment. Multivariate analysis showed the following factors to be significantly associated with better survival: relapse at one site (P=0.0006), large-cell histology (P=0.012), initial prognostic group A or B with lactate dehydrogenase level below twice the normal value (P=0.005), and time to relapse more than 6 months (P=0.04).

Loading Paediatric Onco Hematology Unit collaborators
Loading Paediatric Onco Hematology Unit collaborators